Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
318 hedge funds and large institutions have $10.5B invested in Array Biopharma Inc in 2019 Q2 according to their latest regulatory filings, with 126 funds opening new positions, 69 increasing their positions, 96 reducing their positions, and 71 closing their positions.
115% more funds holding in top 10
Funds holding in top 10: 13 → 28 (+15)
92% more capital invested
Capital invested by funds: $5.5B → $10.5B (+$5.05B)
77% more first-time investments, than exits
New positions opened: 126 | Existing positions closed: 71
19% more funds holding
Funds holding: 268 → 318 (+50)
12% less call options, than puts
Call options by funds: $141M | Put options by funds: $160M
28% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 96
Top Buyers
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
+$163M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$106M |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
+$96.8M |
| 4 |
PC
Paulson & Co
New York
|
+$92M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$90M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$368M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$225M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$155M |
| 4 |
PA
Perceptive Advisors
New York
|
-$89.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$77.4M |
ARRY Hedge Fund Activity: Q2 2019 in Review
318 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q2 2019, worth a combined $10.5B — up 92% from $5.5B a quarter earlier.
Buyers outnumbered sellers: 126 funds opened new ARRY positions and 71 closed out — a net gain of 55 holders — while 69 added to existing stakes and 96 trimmed.
The largest buyer was Davidson Kempner Capital Management, opening a new position worth an estimated $163M. The largest seller was Fidelity Investments, cutting an estimated $368M.
- 318 institutional investors held Array Biopharma Inc (ARRY) as of Q2 2019, up from 268 in Q1 2019.
- Funds reported $10.5B of Array Biopharma Inc stock for Q2 2019, up 92% quarter-over-quarter.
- 126 funds opened new Array Biopharma Inc positions in Q2 2019 and 71 closed out, a net change of +55 holders.
- The largest Array Biopharma Inc buyer in Q2 2019 was Davidson Kempner Capital Management, an estimated $163M added.
- The largest Array Biopharma Inc seller in Q2 2019 was Fidelity Investments, an estimated $368M sold.
Based on aggregated 13F filings for Q2 2019.